Novocure Ltd. | Small-cap | Healthcare
$16.89
-4.63%
| Novocure Stock Comparison:
Novocure vs Abbott LaboratoriesNovocure vs Boston ScientificNovocure vs UFP TechnologiesNovocure vs Alphatec HoldingsNovocure vs EnovisNovocure vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 605.2M
Gross Profit 468.0M 77.33%
Operating Income -170.5M -28.17%
Net Income -168.6M -27.86%
EPS (Diluted) -$1.56

Balance Sheet Metrics

Total Assets 1.2B
Total Liabilities 880.6M
Shareholders Equity 360.2M
Debt to Equity 2.44

Cash Flow Metrics

Operating Cash Flow -20.8M
Free Cash Flow -69.2M

Revenue & Profitability Trend

Novocure Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue605.2M509.3M537.8M535.0M494.4M
Cost of Goods Sold137.2M128.3M114.9M114.9M106.5M
Gross Profit468.0M381.1M423.0M420.2M387.9M
Operating Expenses638.5M613.9M512.5M464.5M357.5M
Operating Income-170.5M-232.9M-89.5M-44.3M30.4M
Pre-tax Income-131.2M-191.7M-81.8M-52.1M18.1M
Income Tax37.5M15.3M10.7M6.3M-1.7M
Net Income-168.6M-207.0M-92.5M-58.4M19.8M
EPS (Diluted)-$1.56-$1.95-$0.88-$0.56$0.18

Income Statement Trend

Novocure Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets1.1B1.0B1.1B1.1B999.4M
Non-Current Assets134.2M111.7M80.1M66.0M52.5M
Total Assets1.2B1.1B1.2B1.1B1.1B
Liabilities
Current Liabilities756.4M179.1M158.8M142.6M113.6M
Non-Current Liabilities124.2M604.5M591.7M586.4M461.8M
Total Liabilities880.6M783.6M750.5M729.0M575.5M
Equity
Total Shareholders Equity360.2M362.5M441.2M410.5M476.5M

Balance Sheet Composition

Novocure Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-168.6M-207.0M-92.5M-58.4M19.8M
Operating Cash Flow-20.8M-88.9M18.8M51.1M73.2M
Investing Activities
Capital Expenditures-42.9M-27.1M-21.4M-24.2M-15.0M
Investing Cash Flow-140.2M184.1M-140.0M-144.8M-472.8M
Financing Activities
Dividends Paid-----
Financing Cash Flow88.2M4.4M5.2M4.5M411.8M
Free Cash Flow-69.2M-100.4M9.4M58.6M84.2M

Cash Flow Trend

Novocure Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -10.90
Forward P/E -11.07
Price to Book 5.12
Price to Sales 2.98
PEG Ratio -11.07

Profitability Ratios

Profit Margin -26.41%
Operating Margin -24.43%
Return on Equity -45.52%
Return on Assets -8.64%

Financial Health

Current Ratio 1.46
Debt to Equity 192.49
Beta 0.75

Per Share Data

EPS (TTM) -$1.51
Book Value per Share $3.25
Revenue per Share $5.73

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
nvcr1.9B-10.905.12-45.52%-26.41%192.49
Abbott Laboratories 231.9B17.314.7530.65%31.89%27.09
Boston Scientific 149.9B73.946.759.50%11.58%52.16
UFP Technologies 1.9B29.895.2019.36%11.59%55.05
Alphatec Holdings 1.6B-9.63-18.581,144.21%-25.77%-6.76
Enovis 1.7B-2.010.66-27.35%-37.65%55.68

Financial data is updated regularly. All figures are in the company's reporting currency.